Literature DB >> 1954331

Altered renal calcium handling in hypercalcemia of malignancy.

K R Tuttle1, R T Kunau, N Loveridge, G R Mundy.   

Abstract

It has been controversial whether increased renal tubular calcium reabsorption contributes to hypercalcemia in patients with malignancies. Moreover, whether this abnormality is associated with volume depletion, a parathyroid hormone-like effect, or other mechanisms has not been clarified. Eight consecutive patients with hypercalcemia due to a variety of tumor types were studied in detail. The glomerular filtration rate (iothalamate clearance) was reduced in all patients (0.98 +/- 0.10 (mean +/- SE) mL/s.1.73 m2; P less than 0.001) compared with normal controls (N = 9) (1.93 +/- 0.08 mL/s.1.73 m2), but it was similar to that in controls matched for renal insufficiency (N = 6) (1.15 +/- 0.05 mL/s.1.73 m2). During hypercalcemia produced by calcium infusion, urinary calcium excretion (millimoles of calcium per liter of glomerular filtrate) was increased in controls with renal insufficiency compared to those with normal renal function (P = 0.028). In all patients with hypercalcemia of malignancy, urinary calcium excretion was decreased compared with controls with renal insufficiency, but it was low in only five of eight patients compared with normal controls. Extracellular fluid volume (iothalamate volume of distribution) was not decreased in any patient, and urinary cAMP and/or plasma parathyroid hormone-like bioactivity were increased in six of eight patients. After treatment with an inhibitor of bone resorption, aminopropylidene 1,1 diphosphonate, abnormal renal calcium handling was not detected if the serum calcium normalized. It was concluded that increased renal tubular calcium reabsorption was consistently present in patients with hypercalcemia of malignancy compared with controls matched for renal insufficiency, but the proportion with the abnormality was underestimated if normal controls were used.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1954331     DOI: 10.1681/ASN.V22191

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  6 in total

1.  Dangerous nutrition? Calcium, vitamin D, and shark cartilage nutritional supplements and cancer-related hypercalcemia.

Authors:  Ruth Lagman; Declan Walsh
Journal:  Support Care Cancer       Date:  2003-01-15       Impact factor: 3.603

2.  Multiple myeloma in Nigeria: a multi-centre epidemiological and biomedical study.

Authors:  Odunukwe Nkiruka Nnonyelum; Madu Jude Anazoeze; Nnodu Obigeli Eunice; Okocha Onyichide Emmanuel; Akingbola Titilola Stella; Asuquo Inyama Marcus; Balogun Modupe Taiwo; Kalejaiye Olufunto Olufela; Aneke John Chinawaeze; Joseph Aondowase Orkuma; Gwarzo Gwarzo Dalhat; Ujah Innocent Otobo
Journal:  Pan Afr Med J       Date:  2015-11-24

3.  TRPV2-induced Ca2+-calcineurin-NFAT signaling regulates differentiation of osteoclast in multiple myeloma.

Authors:  Hua Bai; Huayuan Zhu; Qing Yan; Xuxing Shen; Xiupan Lu; Juejin Wang; Jianyong Li; Lijuan Chen
Journal:  Cell Commun Signal       Date:  2018-10-16       Impact factor: 5.712

Review 4.  Metabolic Disorders in Multiple Myeloma.

Authors:  Maria Gavriatopoulou; Stavroula A Paschou; Ioannis Ntanasis-Stathopoulos; Meletios A Dimopoulos
Journal:  Int J Mol Sci       Date:  2021-10-22       Impact factor: 5.923

Review 5.  Multiple myeloma/hypercalcemia.

Authors:  Babatunde O Oyajobi
Journal:  Arthritis Res Ther       Date:  2007       Impact factor: 5.156

Review 6.  Pathophysiological role of calcium channels and transporters in the multiple myeloma.

Authors:  Tingting Li; Junmin Chen; Zhiyong Zeng
Journal:  Cell Commun Signal       Date:  2021-09-27       Impact factor: 5.712

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.